Project Grant R01CA299966
Award Date 5/15/26
Completion Date 4/30/31
Dollars Obligated $593K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oklahoma City, OK 73104, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $160,093 Project Grant effective May 1, 2026, through April 30, 2028, under the Cancer Cause and Prevention Research program (CFDA 93.393). The grant supports research investigating perceptions and informational needs regarding risk-based prostate cancer screening among screening-eligible men. The research addresses disparities in prostate-specific antigen (PSA) screening practices, particularly among...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Oklahoma Health Sciences Center (OUHSC) a Project Grant of $361,695 under the Cancer Treatment Research program (CFDA 93.395) for the period September 1, 2025, through August 31, 2029. This NCI Research Specialist (Clinician Scientist) Award supports the principal investigator's efforts to advance cancer screening and clinical trial enrollment through multiple integrated initiatives. The award protects...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $604,616 Project Grant to The Johns Hopkins University, effective May 12, 2026 through April 30, 2031, under the Cancer Cause and Prevention Research program (CFDA 93.393). This award supports the establishment of the Prostate Cancer Cohort Consortium (PC3), a collaborative epidemiologic initiative designed to improve precision risk stratification and prevention strategies for prostate cancer. The project integrates ten...
- Federal Project Grant Award Summary The National Cancer Institute awarded The Johns Hopkins University a $354,658 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025 through July 31, 2030. This award supports fundamental research investigating subclonal P27 (CDKN1B) loss as a driver of aggressive prostate cancer, with particular focus on understanding health disparities affecting Black or African American males who experience prostate cancer mortality...
- Project Grant Summary Georgetown University received a $663,383 Project Grant award from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) on August 1, 2025, to support proactive outreach and streamlined genetic testing initiatives for prostate cancer survivors. The project, extending through July 31, 2030, addresses the critical gap between expanded germline genetic testing guidelines and low testing rates among the nation's over three million...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Oklahoma Health Sciences Center a Project Grant of $424,480 under the Cancer Treatment Research program (CFDA 93.395) on September 11, 2025, with an ultimate completion date of August 31, 2029. The award supports the principal investigator's research leadership activities and clinical trial development focused on improving lung cancer care in Oklahoma, where mortality rates significantly exceed the national...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Michigan $682,272 under the Cancer Cause and Prevention Research program (CFDA 93.393) on September 1, 2025, for a two-year project (completion date August 31, 2027) to assess the feasibility and acceptability of a multifaceted electronic health record (EHR)-integrated mobile health intervention designed to reduce post-operative readmissions following radical cystectomy. The intervention consists of an...
- Federal Grant Award Summary The National Cancer Institute awarded a $371,161 Project Grant to the University of Colorado-Denver under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 1, 2025, for a two-year performance period concluding August 31, 2027. The award funds the development of artificial intelligence (AI) algorithms designed to improve cervical cancer screening in low-resource settings. Specifically, the project will create advanced AI risk stratification...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Oklahoma Health Sciences Center a Project Grant of $376,490 under the Cancer Treatment Research program (CFDA 93.395) beginning July 1, 2025 and concluding June 30, 2027. This award supports research and development of a novel therapeutic combination strategy targeting cervical cancer through the integration of a C-MYC inhibitor (MYCI975) with SHETA2, an investigational heat shock protein inhibitor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pittsburgh a $649,620 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective May 1, 2026, through April 30, 2031. This research project examines the impacts of Medicare Advantage insurance coverage on cancer care access, quality, and outcomes for older adults with the four most prevalent cancers: breast, colorectal, lung, and prostate. The research addresses a...